Dr Jonathan Spicer speaks with ecancer about the surgical outcomes from his CheckMate 816 study, comparing Nivolumab (NIVO) plus chemotherapy vs chemotherapy alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
He begins by explaining that treatment options for patients with operable NSCLC have been scarce aside from conventional chemotherapy, with Checkmate 816 being the first study to report the addition of immunotherapy in the pre-operative setting.
Dr Spicer reports that the pathological complete response rate was dramatically higher in patients who received immunotherapy plus chemotherapy before surgery indicating a far more efficacious treatment regimen.
On top of this, he reports that patients who received the chemotherapy and immunotherapy had a lower rate of requiring a pneumo-nectomy, a higher rate of complete resection and also with no adverse events signalled.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.